June 11, 2015—A member of the House Energy & Commerce Committee said at a drug industry organized “summit” today she hopes that forthcoming 340B program omnibus guidance can be the basis for an “ongoing conversation among stakeholders” about the drug pricing program’s future.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)